N
PRAH

Natixis’s PRA Health Sciences, Inc. PRAH Stock Holding History

Natixis’s Portfolio PRAH Stock Details PRAH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-875,416
Closed -$145M – 1308
2021
Q2 		$145M Buy
875,416
+691,476
+376% +$115M 0.63% 30
2021
Q1 		$28.2M Buy
+183,940
New +$25M 0.09% 209
2020
Q4 		– Sell
-49,570
Closed -$5.03M – 1122
2020
Q3 		$5.03M Sell
49,570
-30,230
-38% -$3.08M 0.04% 279
2020
Q2 		$7.76M Buy
+79,800
New +$7.43M 0.06% 223
2020
Q1 		– Sell
-31,342
Closed -$3.45M – 937
2019
Q4 		$3.45M Buy
+31,342
New +$3.22M 0.02% 467
2019
Q3 		– Sell
-38,537
Closed -$3.82M – 957
2019
Q2 		$3.82M Sell
38,537
-81,968
-68% -$7.82M 0.03% 371
2019
Q1 		$13M Buy
120,505
+107,804
+849% +$11.3M 0.08% 231
2018
Q4 		$1.17M Sell
12,701
-28,807
-69% -$2.91M 0.01% 496
2018
Q3 		$4.57M Buy
+41,508
New +$4.32M 0.03% 387

Other funds holding PRAH

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Natixis's PRAH Position: Q3 2021 in Review

Natixis sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 875,416 shares — an estimated $145M sold.

Natixis first reported a position in PRAH in Q3 2018 and held it in 9 quarters. The position peaked at $145M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.

  • Natixis reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Natixis sold 875,416 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $145M.
  • Natixis first reported a position in PRA Health Sciences, Inc. in Q3 2018 and held it in 9 quarters.
  • Natixis's PRA Health Sciences, Inc. position peaked at $145M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.

Based on Natixis's 13F filing for Q3 2021, filed 12 Nov 2021.